Clinical Trials: Skin Cancer

California

Burbank; East Valley Hematology And Oncology Medical Group, Inc.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Burbank; East Valley Hematology And Oncology Medical Group
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Duarte; City of Hope
PHII-77 NCI#7522: A Phase II Study Evaluating the Efficacy of VEGF Trap in Patients with Recurrent Inoperable Stage III or Stage IV Melanoma

Los Angeles; Usc Norris Comprehensive Cancer Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Los Angeles; Usc Norris Comprehensive Cancer Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Santa Monica; The Angeles Clinic And Research Institution
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Santa Monica; The Angeles Clinic And Research Institution
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Connecticut

Hartford; Saint Francis Hospital And Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Hartford; Saint Francis Hospital And Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Stamford; Hematology Oncology, P.C.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Florida

Jacksonville; Integrat Community Onc Netwrk
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Jacksonville; Integrated Community Oncology Network
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Port St. Lucie; Hematology Oncology Associates Of The Treasure Coast
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Illinois

Elgin; Sherman Health Systems
Phase III randomized study of four weeks of high dose IFN-Alpha2b in Stage T3-T4 or N1 (microscopic) melanoma

Indiana

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase II; Second Line or More

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase II; Second Line Treatment

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase III; First Line Treatment

Beech Grove; American Health Network of Indiana LLC, Oncology Division
Phase III: Randomized, Double Blind, Multicenter Study Comparing MDX_010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A 0201 Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma

Kansas

Hutchinson; Hutchinson Clinic, Pa
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Hutchinson; Hutchinson Clinic, Pa
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Kentucky

Hazard; Kentucky Cancer Clinic
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Maryland

Baltimore; Greater Baltimore Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Massachusetts

Boston; Dana Farber Cancer Institute
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Missouri

St Joseph; St Joseph Oncology Inc
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

St Joseph; St Joseph Oncology Inc
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

New York

New York; Biomedical Research Alliance of New York
Skin cancer- advanced melanoma

Valhalla; New York Medical College
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

North Carolina

Huntersville; Carolina Bio-Oncology
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Pollocksville; Eastern Carolina Internal Medicine
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Pollocksville; Eastern Carolina Internal Medicine
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Ohio

Cincinnati; The Christ Hospital Cancer Center Research
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Oregon

Portland; Providence Portland Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Portland; Providence Portland Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Tennessee

Knoxville; Thompson Cancer Survival Ctr
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Texas

Arlington; Arlington Cancer Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Arlington; Arlington Cancer Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Dallas; Mary Crowley Medical Research Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Dallas; Ut Southwestern
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Dallas; Mary Crowley Medical Research Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Lubbock; Joe Arrington Cancer Research And Treatment Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Lubbock; Joe Arrington Cancer Research And Treatment Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Virginia

Charlottesville; University of Virginia School of Medicine Clinical Trials Office
Evaluation of the Safety and Immunogenicity of Vaccination with Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells, in Patients with Advanced Melanoma HIC #10464 IND# 10825

Charlottesville; University of Virginia
The UVA Cancer Center seeks adult volunteers with melanoma for a

Charlottesville; University of Virginia
Evaluation of the Effects of Local GM-CSF-in-adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes ( HIC # 8380)

Charlottesville; University of Virginia
Phase II Trial for the Evaluation of the Efficacy of Vaccination with Synthetic Melanoma Peptides Administered with GM-CSF-in-adjuvant in Patients with Advanced Melanoma HIC #10049

Newport News; Peninsula Cancer Institute
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Richmond; Virginia Cancer Institute
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Richmond; Virginia Cancer Institute
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

International

Buenos Aires, Argentina; Instituto Médico Especializado Alexander Fleming
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Cordoba, Argentina; Instituto Oncologico De Cordoba
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Santa Fe, Argentina; Isis Clinica Especializada
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Box Hill, Australia; Department Of Medical Oncology, Box Hill Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Coffs Harbour, Australia; Coffs Harbour Health Campus
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Newcastle, Australia; David Maddison Building
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Port Macquarie, Australia; Port Macquarie Base Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Brasschaat, Belgium; Az Klina
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Bruxelles, Belgium; Cliniques Universitaires Saint-Luc
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Charleroi, Belgium; Centre Hospitalier Notre Dame Et Reine Fabiola
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Edegem, Belgium; University Hospital Antwerp
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Gent, Belgium; Universitair Ziekenhuis Gent
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Montreal, Canada; Smbd Jewish General Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Montreal, Canada; Hopital Maisonneuve-Rosemont
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Santiago, Chile; Fundacion Arturo Lopez Perez
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Bordeaux, France; Hopital Saint Andre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Brest, France; Hopital Morvan
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Lyon, France; Hopital Hotel Dieu
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Marseille Cedex 09, France; Hopital Sainte Marguerite
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Nantes, France; Hotel Dieu
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Paris Cedex 10, France; Hopital Saint Louis
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Saint Etienne, France; Chu De Saint Etienne
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Wurzburg, Germany; Universitatsklinikum Wurzburg
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Gyula, Hungary; Pandy Kalman Megyei Korhaz
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Miskolc, Hungary; Semmelweis Korhaz Rendelointezet
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Szegedi, Hungary; Szgedi Tudomanyegyetern
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Haifa, Israel; Rambam Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Holon, Israel; Wolfson Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Jerusalem, Israel; Hadassah Hebrew University Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Genova, Italy; Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Milano, Italy; Istituto Europeo Di Oncologia
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Napoli, Italy; Istituto Nazionale Tumori Fondazione Pascale
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Padova, Italy; Istituto Oncologico Veneto
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Siena, Italy; Azienda Ospedaleira Universitaria Senese S. Maria Alle Scott
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Eindhoven, Netherlands; Catharina Ziekenhuis
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Mb Amsterdam, Netherlands; Vu Medical Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Oslo, Norway; Department Of Clinical Cancer Research
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Gdansk, Poland; Wojewodzkie Centrum Onkologii
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Lodz, Poland; Regionalny Osrodek Onkolologiczy Wojewodzkii Szpital Specjal
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Lublin, Poland; Centrum Onkologii Ziemi Lubelskiej
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Poznan, Poland; Wielkopolskie Centrum Onkologii
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Wroclaw, Poland; Wojewodzki Szpital Specjalistyczny
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Coimbra, Portugal; Ipo De Coimbra Fg E.P.E.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Lisboa, Portugal; Instituto Portugues De Oncologia De Lisboa Fg E.P.E.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Porto, Portugal; Ipo Do Porto Fg E.P.E.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Setubal, Portugal; Hospital De Sao Bernardo
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Barnaul, Russian Federation; Altai Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Moscow, Russian Federation; N. N. Blokhin Russian Cancer Research Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Murmansk, Russian Federation; Murmansk Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Ryazan, Russian Federation; Regional Clinical Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Samara, Russian Federation; Samara Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

St Petersburg, Russian Federation; City Clinical Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

St. Petersburg, Russian Federation; Leningrad Regional Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Stavropol, Russian Federation; Stavropol Regional Clinical Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Voronezh, Russian Federation; Voronezh Regional Clinical Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Johannesburg, South Africa; Sandton Oncology Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Panorama, South Africa; Gvi Oncology Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Port Elizabeth, South Africa; Eastern Cape Oncology Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Pretoria, South Africa; Wilgers Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Saxonwold, South Africa; Medical Oncology Center Of Rosebank
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Canarias, Spain; Hospital Univ. De Canarias
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Malaga, Spain; Hospital Universitario Virgen De La Victoria
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Valencia, Spain; Hospital General Universitario
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Zaragoza, Spain; Hospital Universitario Miguel Servet
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Cherkassy, Ukraine; Cherkassy Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Dnepropetrovsk, Ukraine; Dnepropetrovsk State Medical Academy
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Kiev, Ukraine; Institute Of Oncology Ams Of Ukraine
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Lviv, Ukraine; Lviv State Oncology Regional Treatment And Diagnostic Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Uzhgorod, Ukraine; Uzhgorod National University
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

London, United Kingdom; The Royal Marsden Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Wirral, United Kingdom; Clatterbridge Centre For Oncology
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo